InVivo

Cervical Cancer – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced cervical cancer with radiotherapy and Thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2007.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus (G716/45) on standard radiotherapy in comparison with historic control from the literature reports the results of treatment in stage IIIB-IV cervical cancer.

Patients and Methods

During the period of March 2003 to June 2005. Thirty patients in advanced cervical cancer stage IIIB-IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45) daily dose 15-30 ml orally tid, pc as an additional supportive remedy.

Results

Thirty cases of patients in advanced cervical cancer stage IIIB-IV with poor performance status, the median age in stage IIIB, IVA, IVB were 50 years (range 41-73 years), 50.5 years (45 years, 58 years), 69 years (67 years, 71 years) respectively. The analysis were being categorized and performed on stages IIIB, IVA, IVA with bladder cancer and IVB reporting in corresponding number of cases/total subject (percentage) were 25/30 (83.33%), 2/30 (6.67%), 1/30 (3.33%) and 2/30 (6.67%) respectively. The median tumor size for stages IIIB, IVA and IVB were 5 cm (range 2-10 cm), 5 cm (4,6 cm) and 4 cm (2,6 cm) respectively. The pathological identification had been classified to be squamous cell carcinomas 21/30 (70.00%), adenocarcinomas 7/30 (23.33%), small cell carcinoma 1/30 case (3.33%) and clinically staging IIIB 1/30 case (3.33%). The median time interval between teletherapy and brachtytherapy was 22 days (range 7-41 days). Eventually, 84% of the stage IIIB cases were undergone by prolonged gap of more than 2 weeks of time interval between teletherapy and brachytherapy while the rest of the case (16%) received the optimal time gap of treatments. The initial complete response and partial response after 4-6 weeks of radiotherapy were 84% and 16% respectively. The patterns of failure in stage IIIB revealed in 16% with residual pelvic diseases (< 6 months), 3% with local pelvic recurrence (> 6 months) and 4% with distant metastases. Median follow-up period in stage IIIB was 22 months (range 2-48 months). Low radiation complications were noted, the severe radiation proctitis (grade 3) was found to be 3.33%. It was notable results in the declined BUN/Cr level in cervical cancer patients with underlying renal insufficiency/chronic renal failure patients treated by palliative radiotherapy and Thai herbal tonic solution as an additional supportive remedy had been observed in 2 cases of stage IIIB and 1 case of stage IVA with neither surgical intervention nor hemodialysis.

Conclusion

Our preliminary study in the treatment of advanced cases of Ca. Cervix with palliative radiotherapy and Thai herbal medicine had shown the evidence of initial complete regression of tumour with disappearance of foul smell discharge as high as 84% with low rate of local pelvic recurrence, low distant metastases and low rate of radiation complication. However, the study had a limitation on the number of cases and a short follow up period. Moreover, this treatment modality had shown the benefit on the declination of BUN/Cr level in some cases of those locally advanced stages III B-IV in chronic renal failure caused by chronic ureteric obstruction due to lateral spreading of the cancer pressing on both ureters, without neither surgical intervention nor hemodialysis. The declined BUN/Cr levels were the consequence of the relief of pressure effect on the ureters by the decreasing of the tumour volumes. Palliative radiotherapy with Thai herbal tonic as supportive remedy was safe, cost effective, in addition to the benefit of improval of quality of life without the toxicity of herbal medicine. Therefore, this combination of palliative radiotherapy together with Thai Herbal Medicine would be the alternative option for the palliative treatment of advanced cancer cases with poor performance status or in locally advanced cancer cases. Further studies should be performed in order to confirm this findings with statistical significant conclusion.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Sukachart KIRDPON M.D, Anucha PUAPAIROJ M.D and Pongsiri PRATHNADI M.D

Download

Brain Tumor – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced subependymal oligodendroglioma with radiotherapy and Thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2006.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus complementarity to standard palliative radiotherapy in comparison with historic control from the literature reports in subependymal oligodendrogliomas.

Method

An inoperable subependymal oligodendroglioma in a 14 years old boy being treated by palliative radiotherapy and concurrent with Thai herbal medicine (Vilac Plus) as supportive remedy.

Result

The result revealed complete response of advanced subependymal oligodendroglioma. The patient shows good quality of life until now, 43 months after the diagnosis and starting the treatment. In addition, there is also omprovement of diabetes insipidus and still alive with Karnofsky’s performance status 100%. Currently the follow-up time is 43 months after the initial diagnosis and treatment (craniotomy and tumor biopsy).

Conclusion

The results of radiotherapy of an inoperable subependymal oligodendrogrlioma using Thai herbal medicine as an adjuvant remedy has been very satisfactory with good quality of life. This combination modality of treatment present a very promising and cost effectiveness therapy, leading to the confirmation of the concept of complementary approaches on cancer therapy.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Anucha PUAPAIROJ M.D, Sukachart KIRDPON M.D and Pongsiri PRATHNADI M.D

Download

Lung Cancer – Clinical Trials

Evaluation of the effectiveness of the product the Vilac Plus® Eubiotic Drink G716/45 on Cancers Stage IIIB and IV.

Palliative treatment of advanced lung cancer with radiotherapy and thai herbal medicine as supportive remedy

Clinical trials HE480745 conducted at Srinagarind Public Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Published in The Asean Journal of Radiology, September – December 2006.

Abstract

Objective

To evaluate the supportive effect of Thai herbal medicine, Vilac Plus (G716/45) on standard palliative radiotherapy in advanced stage IIIB-IV lung cancer compare with history control from the literature reports.

Patients and Methods

Thirteen patients in advanced lung cancer stage IIIB-IV with poor performance status were treated by palliative radiotherapy in adjuvant with the Thai herbal tonic solution (Vilac Plus G716/45).

Results

Thirteen patients (8 male, 5 female) in advanced stages lung cancer with poor performance status, stage IIIB 11 cases, stage IV 2 cases. Median age 66 years (range 44.4-83 years). The pathological diagnosis were 5 cases of squamous cell carcinoma, 2 cases of adenocarcinoma and 4 cases of clinically advanced lung cancer as of evidenced by computed tomography chest scan/chest X-ray. The results of treatment 4-6 weeks after radiotherapy revealed 76.92% (10/13 cases) of clinically improvement and 23.08% (3/13 cases) of clinically stable. Overall response rate was 46,15% (6/13) of partial response and 53.85% (7/13 cases) had shown stable diseases. Patterns of failure were found to be locally progressing 46.15% (6/13 cases) at the primary site, 30.77% (4/13 cases) at the locoregional, 23.08% (3/13 cases) at the locoregional with distant metastases. Median follow-up time is 18 months (range 7-50 months). Clinical benefit rate, evaluated at ≤ 15 months was 72.72%. However the median survival period analysis required longer follow-up and more detail assessment.

Conclusion

The results of this study are promising in the aspect of good quality of life and preferable because of the cost effectiveness to be used as an adjuvant for radiotherapy.

Montien PESEE M.D, Wichit KIRDPON Ph.D, Anucha PUAPAIROJ M.D, Sukachart KIRDPON M.D and Pongsiri PRATHNADI M.D

Download